1 / 9

First Presentation

First Presentation. Introduction. Given Pancreatic Cancer Survival <1% of 5 years Fourth leading cancer killer CA19-9 Specificity 85% (PUT SENSITIVITY HERE) 35,240/42,450 die in 2009 Data to acquire Best current test Future methods Demographics. Introduction. Approach

manjit
Télécharger la présentation

First Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. First Presentation

  2. Introduction • Given • Pancreatic Cancer • Survival <1% of 5 years • Fourth leading cancer killer • CA19-9 • Specificity 85% • (PUT SENSITIVITY HERE) • 35,240/42,450 die in 2009 • Data to acquire • Best current test • Future methods • Demographics

  3. Introduction • Approach • Compare current methods quantitatively • Selective targeting using demographics (high risk population) • Credible sources/ large sample size • Implementation • Recommend screening test • Highest sensitivity without sacrificing specificity of CA19-9 • Identify populations at high risk

  4. Graph

  5. Graph

  6. EUS • Improved statistics compared to CA19-9 biomarker • Test widely used so results less biased • Low risk factor • Moderate cost • Low invasiveness compared to most surgical procedures

  7. Future Tests • PAM4 Marker • PAM4 antibody detects for MUC1 protein in pancreas • PAM4 Activity shown by imaging • 4 hours after injection • up to 7 days • MUC1 protein specific to cancerous organs • Test in developmental stage

  8. Recommendations • Suggested use of EUS • High risk individuals (60+, family history, diabetes) • Lifestyle (smoking, obesity) • Healthy individuals with unexplained abdominal pain

  9. Recommendations • PAM4 antibody method • Decreased invasiveness • Increased resolution and accuracy of detection

More Related